Vancouver, Canada (CU)_ InMed Pharmaceuticals Inc., a pioneer in the production, development, and marketing of rare cannabinoids, revealed that it has applied for an international patent application illustrating neuroprotection and improved neuronal function with a rare cannabinoid for treating neurodegenerative disorders including Alzheimer’s Disease, Parkinson’s Disease, and Huntington’s Disease., etc.
This PCT application, named “Compositions and Methods for Treating Neuronal Disorders with Cannabinoids,” describes a rare cannabinoid that may prevent or reduce the course of neurodegenerative illnesses by providing neuroprotection to a group of damaged neurons. Additionally, the PCT application illustrates that the concept cannabis compound can be employed to increase neurite outgrowth, implying that it is capable of improving neuronal function. The PCT application comprises a rare cannabinoid that is new to InMed’s portfolio.
Dr. Eric Hsu, Senior Vice President Pre-Clinical Research & Development at InMed, expressed confidence over the treatment. He said, “We are very encouraged by this initial data demonstrating potential for the use of a rare cannabinoid to improve neuronal function and provide neuroprotection for treating neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease and Huntington’s disease”.
Dr. Eric Hsu also expressed hopes for expanding the company’s patent portfolio and assured for the success of new treatment. He said, “This PCT patent application advances our strategy directed towards researching and developing rare cannabinoids as potential pharmaceutical therapeutics for diseases with high unmet medical needs. Expanding our patent portfolio to include, in addition to cannabinol (CBN), an incremental rare cannabinoid for the potential treatment of major neurodegeneration indications demonstrates our continued commitment to our pharmaceutical programs and the potential of rare cannabinoids in medicine.”
This discovery significantly strengthens InMed’s patent portfolio, which presently comprises twelve patent families devoted to rare cannabinoids, seven to production processes and five to products/formulations. With the purchase of BayMedica, the company progressed its patent portfolio to include new biosynthetic pathways and semi-synthetic production of both natural cannabinoids and cannabinoid analogs. BayMedica is expanding its library of patent-eligible novel cannabis analogs for a variety of medicinal purposes.
The PCT is an international convention on patent law that establishes a standardized method for submitting patent applications in every member state to protect innovations. The PCT now includes 153 member nations, allowing for near-global patent coverage via successful patent prosecution in the United States, Japan, Europe, Canada, Australia, New Zealand, China, Brazil, Russia, and India, among others.